Van Leeuwenhoeck Institute Updates Immuron Research Coverage
November 22 2017 - 9:00AM
Immuron Limited (ASX:IMC) (the “Company”) wishes to advise
investors that Van Leeuwenhoeck Institute, a prominent European and
US-based Life Sciences Research and Analyst firm (“VLI”), has
published an updated Equity Analyst Research Report on the Company
and its R&D programs.
The report provides a full valuation of
Immuron’s Intellectually Property Assets including its current
pipeline of development programs. It also highlights the
high-growth market opportunity for two key diseases for which
Immuron seeks to develop treatments for, Non-Alcoholic
Steatohepatitis (NASH) and C. Difficile, referring to the former as
a “holy grail” and the latter as “underestimated potential.”
The final point within the Report’s Executive
Summary states:
“Based on our NPV valuation, we believe that
Immuron is substantially undervalued at the current share price of
AUD$0.18. We have increased our valuation calculation following a
rerating of both its programs in NASH and CDI. Especially in NASH,
the potential deal size has increased following recent activity in
the area. In our view, the Company’s current total value should be
AUD$270 million, or AUD$2.08 per share compared to our previous
calculation of AUD$197 million. This represents a substantial
upside from the current share price.”
Van Leeuwenhoeck Institute provides expert
independent un-biased equity research on the real value of
innovative life science biotechnology companies in Europe, North
America, Australia and emerging markets for institutional, and
professional investors throughout the US and Europe.
A copy of the Research Note as well as others can be viewed on
the Company website at:
http://www.immuron.com/investor-centre/analyst-reports/
COMPANY CONTACT:
Jerry KanellosChief Executive OfficerPh: +61 (0)3
9824 5254 jerrykanellos@immuron.com |
USA MEDIA CONTACT:
Kate Caruso-SharpeFischTank Marketing and PRUS Ph:
+ 1 646 699 1414kate@fischtankpr.com |
USA INVESTOR RELATIONS:
Jon CunninghamRedChip Companies, Inc.US Ph: +1
(407) 644 4256, (ext. 107)jon@redchip.com |
About Van Leeuwenhoeck Institute:
Van Leeuwenhoeck Institute (VLI) provides
institutional investors and other professional investors with
independent, un-biased research on the real value of innovative
Life Sciences companies. Many institutional and individual
investors will not invest in companies lacking independent
third-party research coverage, yet few investment banks cover this
sector because it requires dedicated expertise.
In spite of the lack of quality knowledge on an
industry-wide basis, there is increased demand for life
science-specific market research as investors are seeking
information about leading companies in the sector in order to make
well-informed investment decisions.
Immuron Limited has engaged VLI to
provide the Company with logistical support services in
support of potential European road shows.
For more information visit:
http://www.leeuwenhoeck.com/
ABOUT IMMURON:Immuron Ltd
(ASX:IMC) is a biopharmaceutical company focused on developing and
commercialising oral immunotherapeutics for the treatment of many
gut mediated diseases. Immuron has a unique and safe
technology platform that enables a shorter development therapeutic
cycle. The Company currently markets and sells Travelan® for
the prevention of travellers’ diarrhea whilst its lead product
candidate IMM-124E is in Phase 2 clinical trials for NASH and
ASH. These products together with the Company’s other
preclinical immunotherapy pipeline products targeting
immune-related diseases currently under development, will meet a
large unmet need in the market. For more information visit:
http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited
to, any statements relating to our growth strategy and product
development programs and any other statements that are not
historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock value. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to
the timing of starting and completing clinical trials;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by
law.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2024 to May 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From May 2023 to May 2024